News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,442 Results
Type
Article (14189)
Company Profile (282)
Press Release (251971)
Section
Business (79496)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50441)
Employer Resources (31)
FDA (5714)
Job Trends (5127)
News (144375)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21632)
ALS (60)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (86)
Approvals (5729)
Artificial intelligence (108)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (139)
Cancer (1288)
Cardiovascular disease (105)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (305)
Cervical cancer (8)
Clinical research (40870)
Collaboration (497)
Compensation (218)
Complete response letters (13)
COVID-19 (1034)
CRISPR (36)
C-suite (141)
Cystic fibrosis (76)
Data (1346)
Denatured (11)
Depression (28)
Diabetes (125)
Diagnostics (1292)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29637)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48101)
Executive appointments (396)
FDA (6331)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (463)
Gene editing (87)
Generative AI (9)
Gene therapy (228)
GLP-1 (353)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6588)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (79)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (200)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (185)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2587)
Medtech (2588)
Mergers & acquisitions (6249)
Metabolic disorders (363)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1188)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1535)
Now hiring (21)
Obesity (185)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (8)
Patents (109)
Patient recruitment (66)
Peanut (35)
People (25488)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14428)
Phase II (19016)
Phase III (12022)
Pipeline (687)
Podcasts (46)
Policy (36)
Postmarket research (852)
Preclinical (6060)
Press Release (30)
Prostate cancer (53)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (272)
Real estate (1414)
Recruiting (12)
Regulatory (8555)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (3)
RSV (10)
Schizophrenia (55)
Series A (91)
Series B (59)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1359)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12003)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (61)
Last 7 days (388)
Last 30 days (1504)
Last 365 days (19995)
2025 (4619)
2024 (20552)
2023 (22414)
2022 (26823)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17215)
Australia (2915)
California (3489)
Canada (1046)
China (321)
Colorado (135)
Connecticut (143)
Delaware (87)
Europe (37015)
Florida (408)
Georgia (106)
Idaho (16)
Illinois (209)
India (8)
Indiana (85)
Iowa (1)
Japan (69)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2746)
Michigan (69)
Minnesota (134)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (874)
New Mexico (12)
New York (949)
North Carolina (516)
North Dakota (4)
Northern California (1535)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (669)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1359)
Tennessee (25)
Texas (400)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (317)
Wisconsin (13)
266,442 Results for "atsena therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
March 12, 2025
·
4 min read
Press Releases
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at The Macula Society’s 48th Annual Meeting
February 6, 2025
·
3 min read
Press Releases
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
January 8, 2025
·
5 min read
Press Releases
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan
November 13, 2024
·
5 min read
Press Releases
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
December 16, 2024
·
4 min read
Press Releases
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
·
1 min read
Press Releases
Atsena Therapeutics to Present ATSN-201 Safety and Efficacy Data at the American Academy of Ophthalmology 2024 Annual Meeting
October 10, 2024
·
3 min read
Drug Development
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
Atsena Therapeutics today announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
May 1, 2024
·
5 min read
Press Releases
Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair
July 16, 2024
·
2 min read
Drug Development
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
Atsena Therapeutics announced dosing has been initiated in the second cohort of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis.
March 13, 2024
·
3 min read
1 of 26,645
Next
